Final Results
GlaxoSmithKline PLC
08 February 2007
Issued: 8th February 2007, London
Preliminary Results Announcement for the year ended 31st December 2006
GSK delivers strong 2006 performance with full year EPS up 19% CER (16% reported)
GlaxoSmithKline plc (GSK) today announces its unaudited results for the year ended 31st December 2006. The full
results are presented under 'Income Statement' on pages 7 and 8, and are summarised below.
FINANCIAL RESULTS*
2006 2005 Growth Q4 2006 Q4 2005 Growth
£m £m CER% £% £m £m CER% £%
Turnover 23,225 21,660 9 7 5,959 5,907 9 1
Operating profit 7,808 6,874 17 14 1,700 1,633 19 4
Profit before tax 7,799 6,732 19 16 1,710 1,606 22 6
Earnings per share 95.5p 82.6p 19 16 21.0p 19.8p 22 6
SUMMARY*
• Group turnover up 9% to £23.2 billion, driven by strong US pharmaceuticals performance, up 16%;
resulting in 2006 EPS up 19% in CER terms
• Pharmaceuticals sales also up 9% to £20.1 billion, with strong growth from all major products:
- Seretide/Advair +11% to £3.3 billion - Lamictal +19% to £996 million
- Avandia product group +25% to £1.6 billion - Valtrex +24% to £845 million
- Vaccines +23% to £1.7 billion - Coreg +38% to £779 million
• Consumer Healthcare sales up 6% to £3.1 billion; strong Q4 performance with sales up 9%
• Significant late-stage pipeline progress:
- 4 NCEs, 3 new vaccines and 3 in-licensed assets: HuMax-CD20 (oncology), gepirone ER and XP13512
(CNS disorders) entered late-stage development in the last 12 months
- 31 key product opportunities now in phase III/registration (13 NCEs, 6 vaccines, 12 PLEs)
• 5 major new pharmaceutical product launches expected in 2007:
- Tykerb - new oral treatment for breast cancer
- Cervarix (Europe & International) - a vaccine to prevent cervical cancer (US filing by April)
- Allermist/Avamys - new treatment for allergic rhinitis
- Coreg CR - a once daily treatment for three cardiovascular conditions
- Trexima - new treatment for migraine
• 2006 dividend of 48p (vs 44p in 2005)
• 2007 EPS growth expected to be 8% to 10% in CER terms - driven by continued growth from key products
and improvements in margin.
Commenting on the 2006 performance and GSK's outlook, JP Garnier, Chief Executive Officer, said:
"GSK continues to make progress on all fronts. Sales growth is coming from an ever widening portfolio of fast-growing
products, and sustained improvements in margin have enabled us to deliver a strong financial performance, with EPS up
19% in CER terms. We also have very healthy momentum in our pipeline, with 10 new products added to our late-stage
development efforts in the last 12 months. We now have over 30 significant product opportunities in phase III
development or registration, including five major new products planned for launch this year. For all these reasons, we
look to the future with confidence."
* The Group's practice is to discuss its results in terms of constant exchange rate (CER) growth. All
commentaries compare 2006 results with 2005 in CER terms unless otherwise stated. See 'Accounting
Presentation and Policies' on page 22.
PHARMACEUTICAL UPDATE
Total pharmaceutical turnover grew 9% to £20.1 billion
A strong sales performance in the USA, up 16% to £10.4 billion helped drive total pharmaceutical turnover
growth of 9% in 2006. Sales in Europe grew 1%, to over £5.5 billion, with strong sales from Seretide,
Avandia/Avandamet and vaccines offsetting the impact of generic competition to Lamictal, Imigran and
Zofran, and continued price cuts. International region sales grew 6% to £4.2 billion, with sales in Japan
up 8% to £860 million.
Seretide/Advair sales over £3.3 billion; TORCH data publication in H1 2007
Total sales of Seretide/Advair, for asthma and COPD, rose 11% to £3.3 billion. In the USA, sales grew 13%
to £1.9 billion. In Europe, sales grew 10% to £1.1 billion and in International markets, sales grew 9% to
over £300 million. GSK expects the positive results from TORCH, a COPD mortality study recently filed with
regulators, to be published in a leading medical journal during the first half of 2007.
Avandia product group sales over £1.6 billion with strong growth across all regions
Sales of Avandia products, for the treatment of type 2 diabetes, grew 24% to £1.2 billion in the USA. In
Europe, sales grew 40% to £217 million driven by the increasing use of Avandamet. Sales in International
markets rose 19% to £234 million.
In December, GSK presented data from the landmark ADOPT study, which demonstrated that Avandia is more
effective than metformin, or a sulphonylurea, in long-term blood sugar control in type 2 diabetes. These
data are in addition to those recently presented from the DREAM study, which showed that Avandia can reduce
the risk of progression to type 2 diabetes. Data from both these studies are expected to be filed with
regulatory agencies during the first half of 2007.
Strong 2006 for vaccines with new products driving sales up 23% to £1.7 billion
Overall vaccine sales increased 23% to £1.7 billion, with good performances from all regions: US sales rose
40% to £465 million; European sales grew 20% to £709 million and sales in International were up 13% to £518
million. Key contributors were: Infanrix/Pediarix, GSK's combination vaccines for children, with sales up
29% to £511 million; and sales of hepatitis vaccines, which grew 9% to £479 million, benefiting from a
strong US performance of Havrix, following approval last year for broader paediatric use.
Sales of new vaccines also helped drive overall sales growth. Total sales of Rotarix, for rotavirus,
Boostrix, for prevention of diphtheria, tetanus and whooping cough, and influenza vaccines, Fluarix/
FluLaval, reached £274 million, up 91%.
Lamictal, Valtrex, and Coreg - sales grew 26% to over £2.6 billion
Sales of Lamictal, for the treatment of epilepsy and bipolar disorder, grew 19% to just under £1 billion,
benefiting from its new indication to treat one of the most serious forms of epilepsy - primary generalised
tonic-clonic seizures. Lamictal is also the only medicine with long-term clinical data that demonstrates
that it can delay the onset of depressive episodes of bipolar disorder. In November, GSK submitted
Lamictal XR, a new once daily treatment, with the FDA for treatment of epilepsy. The company intends to
present data on Lamictal XR at the American Academy of Neurology meeting in April.
Sales of Valtrex, for herpes, rose 24% to £845 million, with US sales up 30% to £600 million. Sales of
Coreg, for heart disease, grew strongly, up 38% to £779 million.
High potential products - Avodart, Requip and Boniva deliver combined sales of £579 million
Sales of Requip, for Parkinson's disease/Restless Legs Syndrome (RLS), grew 74% to £268 million and, in
December, the FDA accepted GSK's file for approval of Requip 14hr. Avodart for benign prostatic
hyperplasia (enlarged prostate), continued to perform strongly with sales up 69% to £216 million for the
year. GSK's share of the co-promotion income for Boniva/Bonviva, the only once-monthly medicine for
post-menopausal osteoporosis, was £95 million.
Other products
Total sales of HIV products were £1.5 billion, down 1%. Competition to older products, Combivir (-9% to
£528 million) and Epivir (-21% to £202 million), was partially offset by strong sales growth of new
products Epzicom/Kivexa (>100% to £241 million) and Lexiva (+18% to £131 million).
Sales of Flonase fell 52% to £311 million, reflecting generic competition in the USA, which began in the
first quarter of 2006.
Fourth quarter pharmaceutical sales up 8% to £5.1 billion
A strong fourth quarter performance was driven by US sales, up 15% to £2.6 billion, despite the
introduction of generic competition to Wellbutrin XL 300mg tablet (approximately 60% of Wellbutrin sales)
and Zofran. Fourth quarter sales of Wellbutrin XL were up 9% to £187 million, compared with full year
sales growth of 25% to £798 million. Fourth quarter sales of Zofran declined 19% to £165 million, compared
with full year growth of 3% to £847 million. In Europe, total pharmaceutical sales grew 1% to over £1.4
billion and in International markets rose 3% to £1.1 billion.
PIPELINE UPDATE
GSK expects to launch 5 major new products in 2007:
Tykerb - US launch expected in H1 2007
In December, landmark clinical trial data for Tykerb were published in the New England Journal of Medicine.
Data from the study reported that Tykerb in combination with Xeloda, significantly improved the time to
disease progression for patients with HER2 (ErbB2+) advanced breast cancer whose disease had progressed on
Herceptin. In addition, the study authors concluded that further investigation into earlier use of Tykerb
in the treatment of HER2 positive breast cancer is warranted.
Subject to regulatory approval, GSK plans to launch Tykerb in the USA during the first half of 2007 and in
Europe in the second half of the year. Meanwhile, clinical development of Tykerb continues with seven
phase III trials ongoing to assess the use of Tykerb in treatment of adjuvant and first-line metastatic
breast cancer.
Cervarix - European/International launches expected in H2 2007; US filing by April
GSK expects to launch Cervarix, a new vaccine to prevent cervical cancer, in European and International
markets in the second half of 2007. The company remains on track to file for regulatory approval in the
USA by April.
Earlier this year, GSK announced the initiation of the first head-to-head trial of Cervarix versus
Gardasil, to compare the immune responses to HPV types 16 and 18 in US women 18 to 45 years old. Initial
study results are anticipated in 2008.
Allermist/Avamys - US launch H1 2007; new phase III data to be presented at AAAAI
Allermist/Avamys, a new intranasal steroid to treat the symptoms of seasonal allergic rhinitis and
perennial allergic rhinitis, is expected to be launched in the first half of 2007. GSK will present new
phase III data on the product at the annual meeting of the American Academy of Allergy, Asthma & Immunology
(AAAAI) beginning on 23rd February.
Coreg CR - Launch in Q1 2007; new opportunity to simplify treatment
Coreg CR is a new once-daily, long acting treatment for three cardiovascular conditions: hypertension,
post-myocardial infarction left ventricular dysfunction and mild to severe heart failure. It represents a
significant new opportunity to help simplify treatment for those patients taking multiple medications for
heart conditions, in particular hypertension. The company intends to launch Coreg CR in the first quarter
of 2007.
Trexima - New data submitted to FDA; launch expected H2 2007
A full response to the FDA's recent request for additional information has now been submitted to the
agency. Subject to regulatory approval, GSK expects to launch Trexima, for the treatment of migraine, in
the second half of 2007.
Other important launches/filings
GSK also expects to launch several other important products during the year including, Arixtra to treat
acute coronary syndromes (ACS); Altabax/Altargo, for skin infections, and Entereg for the management of
post-operative ileus.
The company plans to file several new products for approval with regulatory authorities in 2007, including
two major vaccine opportunities: US filing of Rotarix; and European filing of Synflorix (formerly
Streptorix), a vaccine to prevent pneumococcal disease.
GSK also continues to progress development of vaccines for use before, and in the event of, a 'flu
pandemic; and in January, submitted its H5N1 vaccine to European regulators for approval for pre-pandemic
use.
Significant late-stage pipeline progress:
The company now has 31 major product opportunities in phase III development or registration, comprising 13
NCEs, 6 new vaccines and 12 product line extensions.
Major NCEs & vaccines (* entered late-stage in the last 12 months)
Phase III Filed
• ambrisentan (pulmonary arterial hypertension) • Allermist/Avamys (allergic rhinitis)
• belimumab* (lupus) • Altabax/Altargo (skin infections)
• casopitant* (CINV and PONV) • Entereg (POI)
• pazopanib* (renal cell cancer) • Tykerb (breast cancer)
• mepolizumab (hypereosinophilic syndrome) • Cervarix (cervical cancer)
• Promacta * (ITP) • H5N1 pandemic vaccine*
• New generation 'flu vaccine*
• Globorix (Hep B, DTP, Hib and meningitis A+C)
• meningitis (Hib-MenCY-TT) vaccine*
• Synflorix (pneumococcal disease)
New in-licensed assets
• HuMax-CD20*, a high affinity (fully human) monoclonal antibody in late-stage development for chronic
lymphocytic leukaemia and follicular non-Hodgkin's lymphoma; and in phase II development for rheumatoid
arthritis.
• Gepirone ER*, a 5HT1a agonist currently in pre-registration for the treatment of major depressive
disorder (MDD). If approved, gepirone ER would be a first-in-class treatment for MDD, with a
potentially better tolerability profile compared to current anti-depressant therapy.
• XP13512*, a gabapentin prodrug, in phase III development for restless legs syndrome and phase II for
treatment of neuropathic pain. In addition to a convenient dosing regimen, XP13512 could provide a new
treatment option to patients for whom current therapy (dopaminergics) is not appropriate.
CONSUMER HEALTHCARE UPDATE
Sales up 6% to over £3.1 billion; portfolio to be enhanced with 10 product launches in 2007
Consumer Healthcare sales grew 6% to £3.1 billion, with sales in International (+10%) and Europe (+7%),
performing well. Total sales in the USA were flat, with an improved performance seen in the fourth
quarter, with sales up 7% to over £200 million.
• Nutritional healthcare products sales grew 7% to £658 million. Lucozade, grew 14% to £301 million,
and Horlicks, grew 6% to £156 million. Ribena sales were down 1% to £169 million.
• Oral care sales grew 6% to £993 million. Sensodyne grew strongly, up 19% for the year to £257
million. Sales of Aquafresh were down 3% to £283 million.
• Over-the-counter medicine sales grew 5% to £1.5 billion with Panadol and Smoking Control performing
well.
GSK's consumer brand portfolio will be strengthened further in 2007, with the launch of 10 products,
including alli, a new treatment for weight-loss in the USA. In addition, GSK has added two more brands -
Breathe Right nasal strips and FiberChoice dietary fibre supplements - to its portfolio following the
acquisition of CNS, Inc. which was completed in December 2006.
FINANCIAL REVIEW
These results have been prepared under International Financial Reporting Standards as adopted for use in the European
Union (see 'Accounting Presentation and Policies' on page 22).
Operating profit and earnings per share - full year
Operating profit of £7,808 million for the year increased by 17% compared with 2005, and was above turnover growth of
9%, reflecting an improved cost of sales margin (despite higher restructuring costs), flat SG&A costs (including lower
legal and restructuring charges), partially offset by an increase in R&D expenditure and lower other operating income.
Excluding restructuring, R&D expenditure grew in line with turnover growth.
Consumer Healthcare operating profit was down 3%, compared with 2005, as a result of lower profit on product disposals.
Excluding profit on disposals, Consumer Healthcare operating profit grew 4%.
In the year, gains from asset disposals were £169 million (£290 million in 2005), costs for legal matters were £333
million (£430 million in 2005), the fair value movements on the Quest collar and Theravance options resulted in income
of £29 million (£19 million income in 2005) and charges related to restructuring programmes were £205 million (£141
million in 2005). The total operating profit impact of these items was a £340 million charge in 2006, compared with a
£262 million charge in 2005.
Profit after taxation grew by 17%, which was level with the growth in operating profit, and reflected lower net interest
costs, offset by a higher tax rate for the year.
EPS of 95.5 pence increased 19% in CER terms (16% in sterling terms) compared with 2005. The adverse currency impact of
3% on EPS reflected the strength of sterling against other major currencies.
Operating profit and earnings per share - Q4
Operating profit of £1,700 million for the quarter increased by 19% compared with Q4 last year, and was above turnover
growth of 9%, primarily due to flat SG&A (including lower legal costs), lower growth in R&D and higher other operating
income partly offset by a higher cost of sales margin. The cost of sales margin was primarily impacted by higher
restructuring costs, asset impairments and currency, partly offset by favourable pricing.
In the quarter, gains from asset disposals were £3 million (£12 million in 2005), costs for legal matters were £81
million (£132 million in 2005), the fair value movements on the Quest collar and Theravance options resulted in income
of £46 million (£4 million income in Q4 2005) and charges related to restructuring programmes were £132 million (£59
million in 2005). The total operating profit impact of these items was a £164 million charge in 2006, compared with a
£175 million charge in Q4 2005.
Profit after taxation grew by 20% which was marginally higher than the growth in operating profit and reflected lower
net interest costs compared with Q4 2005, largely offset by a higher tax rate.
EPS of 21.0 pence increased 22% in CER terms (6% in sterling terms) compared with Q4 2005. The adverse currency impact
of 16% on EPS reflected the strength of sterling against the other major currencies.
Currencies
The 2006 results are based on average exchange rates, principally £1/$1.85, £1/Euro 1.47 and £1/Yen 215. The period-end
exchange rates were £1/$1.96, £1/Euro 1.48 and £1/Yen 233. Average exchange rates for Q4 2006 were £1/$1.94, £1/Euro
1.50 and £1/Yen 227. If the US dollar and Euro exchange rates were to hold at the Q4 average level for 2007, the
adverse currency impact on EPS growth for the full-year would be around 4%.
Dividend
The Board has declared a fourth interim dividend of 14 pence per share resulting in a dividend for the year of 48 pence,
a four pence increase over the dividend of 44 pence per share for 2005. The equivalent interim dividend receivable by
ADR holders is 55.1628 cents per ADS based on an exchange rate of £1/$1.9701. The dividend will have an ex-dividend
date of 14th February 2007, a record date of 16th February 2007 and will be paid on 12th April 2007.
2007 earnings guidance
GSK expects 2007 EPS growth to be 8% to 10% in CER terms.
Share buy-back programme
GSK repurchased £1,348 million of shares in 2006, to be held as Treasury shares. The company completed its second £4
billion share repurchase programme in September, and in October commenced a new share buy-back programme totalling £6
billion. This programme is expected to be completed over a three year period including £2 billion in 2007. The exact
amount and timing of future purchases, and the extent to which repurchased shares will be held as Treasury shares
rather than being cancelled, will be determined by the company and is dependent on market conditions and other factors.
GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to
improving the quality of human life by enabling people to do more, feel better and live longer. For company information
including a copy of this announcement and details of the company's updated product development pipeline, visit GSK at
www.gsk.com.
Enquiries: UK Media Philip Thomson (020) 8047 5502
Alice Hunt (020) 8047 5502
Gwenan White (020) 8047 5502
US Media Nancy Pekarek (215) 751 7709
Mary Anne Rhyne (919) 483 2839
Patricia Seif (215) 751 7709
European Analyst / Investor Anita Kidgell (020) 8047 5542
David Mawdsley (020) 8047 5564
Sally Ferguson (020) 8047 5543
US Analyst / Investor Frank Murdolo (215) 751 7002
Tom Curry (215) 751 5419
Brand names appearing in italics throughout this document are trademarks of GSK or associated companies with the
exception of Levitra, a trademark of Bayer, Entereg, a trademark of Adolor and Bonviva/Boniva, a trademark of Roche,
which are used under licence by the Group.
Cautionary statement regarding forward-looking statements
Under the safe harbor provisions of the US Private Securities Litigation Reform Act of 1995, the company cautions
investors that any forward-looking statements or projections made by the company, including those made in this
Announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those
projected. Factors that may affect the Group's operations are described under 'Risk Factors' in the 'Operating and
Financial Review and Prospects' in the company's Annual Report 2005.
INCOME STATEMENT
Year ended 31st December 2006
2006 Growth
2005
£m CER% £m
--- --- ---
Turnover:
Pharmaceuticals 20,078 9 18,661
Consumer Healthcare 3,147 6 2,999
--- ---
TURNOVER 23,225 9 21,660
Cost of sales (5,010) 6 (4,764)
--- ---
Gross profit 18,215 9 16,896
Selling, general and administration (7,257) - (7,250)
Research and development (3,457) 11 (3,136)
Other operating income 307 364
--- ---
Operating profit:
Pharmaceuticals 7,125 19 6,159
Consumer Healthcare 683 (3) 715
--- ---
OPERATING PROFIT 7,808 17 6,874
Finance income 287 257
Finance expense (352) (451)
Share of after tax profits of associates and joint ventures 56 52
--- ---
PROFIT BEFORE TAXATION 7,799 19 6,732
Taxation (includes overseas tax of £1,912 million (2005: £1,826 million)) (2,301) (1,916)
Tax rate % 29.5% 28.5%
--- ---
PROFIT AFTER TAXATION FOR THE YEAR 5,498 17 4,816
--- ---
Profit attributable to minority interests 109 127
Profit attributable to shareholders 5,389 4,689
--- ---
5,498 4,816
--- ---
EARNINGS PER SHARE 95.5p 19 82.6p
--- ---
Diluted earnings per share 94.5p 82.0p
--- ---
A fourth interim dividend of 14 pence per share has been declared, making a total of 48 pence per share for the
year (2005: 44 pence per share). The total expected to be absorbed by these dividends is approximately £2,695
million (2005: £2,494 million). See 'Dividends' on page 14.
INCOME STATEMENT
Three months ended 31st December 2006
Q4 2006 Growth Q4 2005
£m CER% £m
--- --- ---
Turnover:
Pharmaceuticals 5,136 8 5,108
Consumer Healthcare 823 9 799
--- ---
TURNOVER 5,959 9 5,907
Cost of sales (1,445) 15 (1,298)
--- ---
Gross profit 4,514 7 4,609
Selling, general and administration (1,934) - (2,040)
Research and development (980) 6 (968)
Other operating income 100 32
--- ---
Operating profit:
Pharmaceuticals 1,501 21 1,440
Consumer Healthcare 199 8 193
--- ---
OPERATING PROFIT 1,700 19 1,633
Finance income 83 85
Finance expense (86) (125)
Share of after tax profits of associates and joint ventures 13 13
--- ---
PROFIT BEFORE TAXATION 1,710 22 1,606
Taxation (505) (455)
Tax rate % 29.5% 28.3%
--- ---
PROFIT AFTER TAXATION FOR THE PERIOD 1,205 20 1,151
--- ---
Profit attributable to minority interests 24 29
Profit attributable to shareholders 1,181 1,122
--- ---
1,205 1,151
--- ---
EARNINGS PER SHARE 21.0p 22 19.8p
--- ---
Diluted earnings per share 20.8p 19.6p
--- ---
PHARMACEUTICAL TURNOVER
Year ended 31st December 2006
Total USA Europe International
-------------- --------------- ------------- -------------
£m CER% £m CER% £m CER% £m CER%
------ ----- ------ ----- ---- ----- ---- -----
RESPIRATORY 4,995 - 2,461 (3) 1,697 3 837 4
Seretide/Advair 3,313 11 1,870 13 1,133 10 310 9
Flixotide/Flovent 659 5 298 16 173 (8) 188 2
Serevent 291 (10) 86 (16) 140 (13) 65 5
Flixonase/Flonase 311 (52) 184 (63) 51 (15) 76 (14)
CENTRAL NERVOUS SYSTEM 3,642 15 2,588 28 595 (15) 459 2
Seroxat/Paxil 620 4 175 35 149 (20) 296 5
Paxil IR 448 (5) 19 11 149 (20) 280 4
Paxil CR 172 37 156 38 - - 16 25
Wellbutrin 900 24 882 24 2 - 16 7
Wellbutrin IR, SR 102 12 89 14 2 - 11 -
Wellbutrin XL 798 25 793 25 - - 5 25
Imigran/Imitrex 711 3 551 11 118 (18) 42 (12)
Lamictal 996 19 765 37 175 (22) 56 2
Requip 268 74 176 >100 81 21 11 25
ANTI-VIRALS 2,827 10 1,354 7 855 11 618 16
HIV 1,515 (1) 700 (7) 621 3 194 8
Combivir 528 (9) 238 (14) 217 (4) 73 -
Trizivir 268 (11) 141 (13) 113 (7) 14 (7)
Epivir 202 (21) 69 (25) 90 (26) 43 (2)
Ziagen 117 (13) 48 (11) 41 (24) 28 4
Agenerase, Lexiva 131 18 74 7 48 40 9 14
Epzicom/Kivexa 241 >100 125 49 97 >100 19 >100
Herpes 965 19 610 30 144 4 211 3
Valtrex 845 24 600 30 109 12 136 10
Zovirax 120 (6) 10 67 35 (15) 75 (7)
Zeffix 162 12 13 8 23 10 126 13
Relenza 91 >100 - - 62 >100 29 >100
METABOLIC 1,875 27 1,277 30 252 33 346 12
Avandia 1,399 23 1,068 26 125 13 206 13
Avandamet 204 17 86 (22) 92 >100 26 41
Avandaryl 42 - 40 - - - 2 -
Bonviva/Boniva 95 >100 83 >100 12 >100 - -
VACCINES 1,692 23 465 40 709 20 518 13
Hepatitis 479 9 161 21 227 2 91 8
Influenza 170 60 91 >100 36 - 43 27
Infanrix/Pediarix 511 29 172 20 281 40 58 12
Boostrix 60 >100 41 >100 15 88 4 67
CARDIOVASCULAR AND UROGENITAL 1,636 24 1,072 42 395 (4) 169 13
Coreg 779 38 773 38 - - 6 20
Levitra 43 8 41 20 1 (75) 1 (100)
Avodart 216 69 131 >100 69 25 16 67
Arixtra 58 >100 32 >100 23 >100 3 >100
Fraxiparine 209 (1) - - 179 - 30 (6)
ANTI-BACTERIALS 1,369 (9) 217 (15) 628 (12) 524 (2)
Augmentin 570 (14) 94 (31) 268 (15) 208 -
Zinnat/Ceftin 164 (16) 12 20 82 (27) 70 (5)
ONCOLOGY AND EMESIS 1,069 7 836 12 153 (7) 80 (11)
Zofran 847 3 679 8 107 (14) 61 (16)
Hycamtin 113 15 72 11 34 26 7 17
OTHER 973 (5) 83 19 263 (19) 627 (1)
Zantac 232 (2) 72 28 52 (19) 108 (7)
-------------- -------------- -------------- --------------
20,078 9 10,353 16 5,547 1 4,178 6
-------------- -------------- -------------- --------------
Pharmaceutical turnover includes co-promotion income.
PHARMACEUTICAL TURNOVER
Three months ended 31st December 2006
Total USA Europe International
-------------- --------------- ------------- -------------
£m CER% £m CER% £m CER% £m CER%
------ ----- ------ ----- ---- ----- ---- -----
RESPIRATORY 1,269 (3) 616 (7) 433 1 220 -
Seretide/Advair 862 9 493 11 293 8 76 1
Flixotide/Flovent 172 7 79 22 42 (12) 51 4
Serevent 74 (9) 22 (17) 33 (13) 19 11
Flixonase/Flonase 48 (69) 17 (85) 11 (15) 20 (8)
CENTRAL NERVOUS SYSTEM 915 13 660 25 137 (17) 118 (3)
Seroxat/Paxil 163 11 49 72 35 (10) 79 (1)
Paxil IR 113 - 3 - 35 (10) 75 -
Paxil CR 50 50 46 59 - - 4 (25)
Wellbutrin 212 9 208 10 - - 4 (25)
Wellbutrin IR, SR 25 13 22 25 - - 3 (33)
Wellbutrin XL 187 9 186 9 - - 1 -
Imigran/Imitrex 174 2 138 12 25 (34) 11 -
Lamictal 257 23 204 39 39 (22) 14 -
Requip 76 62 52 97 21 16 3 -
ANTI-VIRALS 706 9 333 8 210 11 163 11
HIV 360 (5) 168 (7) 146 (3) 46 2
Combivir 119 (14) 56 (15) 48 (9) 15 (20)
Trizivir 61 (14) 32 (16) 25 (13) 4 -
Epivir 43 (24) 15 (23) 18 (34) 10 -
Ziagen 28 (12) 12 (7) 10 (9) 6 (22)
Agenerase, Lexiva 34 12 19 5 12 18 3 50
Epzicom/Kivexa 69 66 33 29 29 100 7 >100
Herpes 242 18 154 30 36 9 52 (5)
Valtrex 212 23 150 28 27 17 35 6
Zovirax 30 (9) 4 >100 9 (10) 17 (22)
Zeffix 42 5 3 33 6 - 33 3
Relenza 37 >100 - - 22 >100 15 >100
METABOLIC 474 34 321 45 69 27 84 7
Avandia 324 25 246 32 30 7 48 4
Avandamet 68 54 32 40 27 75 9 60
Avandaryl 14 - 14 - - - - -
Bonviva/Boniva 34 >100 29 >100 5 - - -
VACCINES 527 31 162 84 200 20 165 10
Hepatitis 128 19 43 38 60 11 25 8
Influenza 107 >100 59 >100 23 (12) 25 >100
Infanrix/Pediarix 136 29 47 37 72 36 17 (11)
Boostrix 18 73 13 63 5 67 - -
CARDIOVASCULAR AND UROGENITAL 421 25 281 44 101 (1) 39 (9)
Coreg 199 39 198 39 - - 1 -
Levitra 12 30 12 44 - - - -
Avodart 61 67 36 95 19 27 6 67
Arixtra 21 >100 12 >100 7 >100 2 -
Fraxiparine 53 (2) - - 44 (4) 9 11
ANTI-BACTERIALS 354 (8) 57 (15) 164 (9) 133 (3)
Augmentin 145 (11) 25 (20) 67 (15) 53 2
Zinnat/Ceftin 42 (19) 3 - 22 (24) 17 (14)
ONCOLOGY AND EMESIS 213 (11) 162 (10) 33 (15) 18 (20)
Zofran 165 (19) 130 (16) 21 (30) 14 (25)
Hycamtin 28 20 18 18 8 50 2 (50)
OTHER 257 2 18 5 80 (7) 159 6
Zantac 55 (5) 16 12 13 (24) 26 (3)
-------------- -------------- -------------- --------------
5,136 8 2,610 15 1,427 1 1,099 3
-------------- -------------- -------------- --------------
Pharmaceutical turnover includes co-promotion income.
CONSUMER HEALTHCARE TURNOVER
Year ended 31st December 2006
2006 Growth
£m CER%
--------- ---------
Over-the-counter medicines 1,496 5
Analgesics 380 7
Dermatological 165 4
Gastrointestinal 252 2
Respiratory tract 172 12
Smoking control 353 7
Natural wellness support 132 -
Oral care 993 6
Nutritional healthcare 658 7
--------- ---------
Total 3,147 6
--------- ---------
CONSUMER HEALTHCARE TURNOVER
Three months ended 31st December 2006
Q4 2006 Growth
£m CER%
--------- ---------
Over-the-counter medicines 409 9
Analgesics 95 9
Dermatological 43 15
Gastrointestinal 63 3
Respiratory tract 54 8
Smoking control 103 18
Natural wellness support 38 11
Oral care 258 10
Nutritional healthcare 156 5
--------- ---------
Total 823 9
--------- ---------
FINANCIAL REVIEW - INCOME STATEMENT
Operating profit
2006 2005 Growth
---------------------- -------------------- ----------------
% of % of
£m turnover £m turnover CER% £%
------ ------ ------ ------ ------ -----
Turnover 23,225 100.0 21,660 100.0 9 7
Cost of sales (5,010) (21.6) (4,764) (22.0) 6 5
Selling, general and administration (7,257) (31.2) (7,250) (33.5) - -
Research and development (3,457) (14.9) (3,136) (14.5) 11 10
Other operating income 307 1.3 364 1.7
------ ------ ------ ------ ------ ----
Operating profit 7,808 33.6 6,874 31.7 17 14
------ ------ ------ ------ ------ ----
Overall, the operating margin increased 1.9 percentage points as sterling operating profit increased 14% on a sterling
turnover growth of 7% reflecting lower growth in cost of sales and flat SG&A costs, partially offset by an increase in R
&D expenditure and lower other operating income.
Cost of sales declined as a percentage of turnover by 0.4 percentage points, reflecting favourable price and regional
mix.
SG&A costs were level with 2005 benefiting from lower legal charges and restructuring costs. Excluding these items SG&A
costs grew 3% reflecting the continuing benefits of cost saving programmes.
R&D expenditure increased 11% partly as a result of higher charges related to restructuring programmes. Excluding
restructuring costs R&D grew 8%. Pharmaceuticals R&D expenditure excluding restructuring costs represented 16.2% (2005:
16.2%) of pharmaceutical turnover.
Other operating income includes royalty income, equity investment disposals and impairments, product disposals and fair
value adjustments to the Quest collar and Theravance options. Other operating income was £307 million in 2006 compared
with £364 million in 2005. The decrease is primarily due to lower product and asset disposal profits partially offset
by the favourable fair value movement to the Quest collar and Theravance options.
Taxation
The charge for taxation on profit amounting to £2,301 million, represents an effective tax rate of 29.5%, (2005 -
28.5%). The Group balance sheet at 31st December 2006 included a tax payable liability of £621 million and a tax
recoverable asset of £186 million.
As reported last year, GSK's largest unresolved tax issues were with the US Internal Revenue Service (IRS) and UK HM
Revenue and Customs (HMRC) in respect of transfer prices related to the Glaxo heritage products.
On 11th September 2006, GSK and the IRS agreed to a resolution of their dispute. Under the agreement, GSK has made
gross payments to the IRS of approximately $3.3 billion. The final net cash cost to the Group is approximately $3.1
billion, which covers federal, state and local taxes, interest and the benefit of tax relief on the payments made. The
settlement resolved all the transfer pricing issues in dispute for the period 1989 - 2000, which were due to go to trial
in February 2007, and also covers the subsequent years 2001 - 2005. GSK had previously made provision for the dispute
and this settlement did not have any significant impact on the company's reported earnings or tax rate for the year.
GSK continues to be in dispute with HMRC primarily in respect of transfer pricing and Controlled Foreign Companies
legislation matters for the years 1994 to date and the parties are now preparing for litigation. HMRC has not formally
quantified its claims in respect of these matters but there continues to be a wide difference between the Group and HMRC
positions on these matters.
GSK has open issues in Japan and Canada, which were the subject of court proceedings in 2006. In Japan the tax
authorities are claiming approximately Yen 39 billion (£169 million) in respect of transactions in 1998. GSK has paid
the tax claimed, as required by law, and applied for a refund. A court decision is expected in late March 2007. A
court decision in the Group's dispute with the Canadian Revenue Authority over the pricing of Zantac in the years 1989 -
1993 is expected in the first half of 2007.
GSK uses the best advice in determining its transfer pricing methodology and in seeking to manage transfer pricing
issues to a satisfactory conclusion and, on the basis of external professional advice, continues to believe that it has
made adequate provision for the liabilities likely to arise from open assessments. The ultimate liability for such
matters may vary from the amounts provided and is dependent upon the outcome of litigation proceedings and negotiations
with the relevant tax authorities.
Weighted average number of shares
2006 2005
millions millions
---- ----
Weighted average number of shares - basic 5,643 5,674
Dilutive effect of share options and share 57 46
awards
---- ----
Weighted average number of shares - diluted 5,700 5,720
---- ----
Q4 2006 Q4 2005
millions millions
---- ----
Weighted average number of shares - basic 5,618 5,657
Dilutive effect of share options and share awards 51 53
---- ----
Weighted average number of shares - diluted 5,669 5,710
---- ----
The number of shares in issue, excluding those held by the ESOP Trusts and those held as Treasury shares at 31st
December 2006, was 5,603 million (31st December 2005: 5,653 million).
Dividends
Paid/ Pence per
payable share £m
---- ---- ----
2006
First interim 6th July 2006 11 619
Second interim 5th October 2006 11 620
Third interim 4th January 2007 12 671
Fourth interim 12th April 2007 14 785
---- ----
48 2,695
---- ----
2005
First interim 7th July 2005 10 568
Second interim 6th October 2005 10 567
Third interim 5th January 2006 10 568
Fourth interim 6th April 2006 14 791
---- ----
44 2,494
---- ----
The liability for an interim dividend is only recognised when it is paid, which is usually after the accounting period
to which it relates. The 2006 financial statements recognise the dividends paid in 2006, namely the third and fourth
interim dividends for 2005 and the first and second interim dividends for 2006, which total £2,598 million (2005: £2,390
million).
STATEMENT OF RECOGNISED INCOME AND EXPENSE
2006 2005
£m £m
---- ----
Exchange movements on overseas net assets (390) 203
Tax on exchange movements (78) 99
Fair value movements on available-for-sale investments 84 (1)
Deferred tax on fair value movements on available-for-sale investments (15) (10)
Exchange movements on goodwill in reserves 31 9
Actuarial gains/(losses) on defined benefit plans 429 (794)
Deferred tax on actuarial movements in defined benefit plans (161) 257
Fair value movements on cash flow hedges (5) (4)
Deferred tax on fair value movements on cash flow hedges 2 1
---- ----
Net losses recognised directly in equity (103) (240)
Profit for the year 5,498 4,816
---- ----
Total recognised income and expense for the year 5,395 4,576
---- ----
Total recognised income and expense for the year attributable to:
Shareholders 5,307 4,423
Minority interests 88 153
---- ----
5,395 4,576
---- ----
BALANCE SHEET
31st December 2006 31st December 2005
£m £m
ASSETS ---- ----
Non-current assets
Property, plant and equipment 6,930 6,652
Goodwill 758 696
Other intangible assets 3,293 3,383
Investments in associates and joint ventures 295 276
Other investments 441 362
Deferred tax assets 2,123 2,214
Other non-current assets 721 438
---- ----
Total non-current assets 14,561 14,021
---- ----
Current assets
Inventories 2,437 2,177
Current tax recoverable 186 416
Trade and other receivables 5,317 5,348
Liquid investments 1,035 1,025
Cash and cash equivalents 2,005 4,209
Assets held for sale 12 2
---- ----
Total current assets 10,992 13,177
---- ----
TOTAL ASSETS 25,553 27,198
---- ----
LIABILITIES
Current liabilities
Short-term borrowings (718) (1,200)
Trade and other payables (4,871) (5,147)
Current tax payable (621) (2,269)
Short-term provisions (1,055) (895)
---- ----
Total current liabilities (7,265) (9,511)
---- ----
Non-current liabilities
Long-term borrowings (4,772) (5,271)
Deferred tax provision (595) (569)
Pensions and other post-employment benefits (2,339) (3,069)
Other provisions (528) (741)
Other non-current liabilities (406) (467)
---- ----
Total non-current liabilities (8,640) (10,117)
---- ----
TOTAL LIABILITIES (15,905) (19,628)
---- ----
NET ASSETS 9,648 7,570
---- ----
EQUITY
Share capital 1,498 1,491
Share premium account 858 549
Other reserves 65 (308)
Retained earnings 6,965 5,579
---- ----
Shareholders' equity 9,386 7,311
Minority interests 262 259
---- ----
TOTAL EQUITY 9,648 7,570
---- ----
RECONCILIATION OF MOVEMENTS IN EQUITY
2006 2005
£m £m
---- ----
Total equity at beginning of year 7,570 5,925
Total recognised income and expense for the year 5,395 4,576
Dividends to shareholders (2,598) (2,390)
Shares issued 316 252
Shares purchased and held as Treasury shares (1,348) (1,000)
Consideration received for shares transferred by ESOP Trusts 151 68
Share-based incentive plans 226 240
Tax on share-based incentive plans 21 25
Changes in minority interest shareholdings 2 (40)
Distributions to minority shareholders (87) (86)
---- ----
Total equity at end of year 9,648 7,570
---- ----
FINANCIAL REVIEW - BALANCE SHEET
Net assets
The book value of net assets increased by £2,078 million from £7,570 million at 31st December 2005 to £9,648 million at
31st December 2006. Net debt increased and the overall tax creditor position decreased following the gross payment of
$3.3 billion (£1.8 billion) under the transfer pricing dispute settlement with the US Internal Revenue Service (see '
Taxation' on page 13). The pension and other post-employment liabilities decreased following improvements in asset
values, further special contributions to the UK and US pension funds and a strengthening of long-term interest rates,
including an increase in the rate used to discount UK pension liabilities from 4.75% to 5.0%.
The carrying value of investments in associates and joint ventures at 31st December 2006 was £295 million, with a market
value of £1,020 million.
Equity
At 31st December 2006, total equity had increased from £7,570 million at 31st December 2005 to £9,648 million. The
increase arises principally from retained earnings and actuarial gains on defined benefit pension plans in the year
partially offset by further purchases of Treasury shares.
At 31st December 2006, the ESOP Trusts held 153.5 million GSK shares against the future exercise of share options and
share awards. The carrying value of £1,999 million has been deducted from other reserves. The market value of these
shares was £2,062 million. At 31st December 2006, GSK also held 235.5 million shares as Treasury shares, at a cost of
£3,147 million, which has been deducted from retained earnings.
CASH FLOW STATEMENT
Year ended 31st December 2006
2006 2005
£m £m
---- ----
Profit after tax 5,498 4,816
Tax on profits 2,301 1,916
Share of after tax profits of associates and joint ventures (56) (52)
Finance income/expense 65 194
Depreciation and other non-cash items 1,138 1,103
Increase in working capital (471) (323)
(Decrease)/increase in other net liabilities (272) 11
---- ----
Cash generated from operations 8,203 7,665
Taxation paid (3,846) (1,707)
---- ----
Net cash inflow from operating activities 4,357 5,958
---- ----
Cash flow from investing activities
Purchase of property, plant and equipment (1,366) (903)
Proceeds from sale of property, plant and equipment 43 54
Purchase of intangible assets (224) (278)
Proceeds from sale of intangible assets 175 221
Purchase of equity investments (57) (23)
Proceeds from sale of equity investments 32 35
Share transactions with minority shareholders (157) (36)
Purchase of businesses, net of cash acquired (273) (1,026)
Disposals of businesses and interests in associates 5 (2)
Investment in associates and joint ventures (13) (2)
Interest received 299 290
Dividends from associates and joint ventures 15 10
---- ----
Net cash outflow from investing activities (1,521) (1,660)
---- ----
Cash flow from financing activities
(Increase)/decrease in liquid investments (55) 550
Proceeds from own shares for employee share options 151 68
Issue of share capital 316 252
Purchase of Treasury shares (1,348) (999)
Increase in long-term loans - 982
Repayment of long-term loans - (70)
Net repayment of short-term loans (739) (857)
Net repayment of obligations under finance leases (34) (36)
Interest paid (414) (381)
Dividends paid to shareholders (2,598) (2,390)
Dividends paid to minority interests (87) (86)
Other financing cash flows 16 53
---- ----
Net cash outflow from financing activities (4,792) (2,914)
---- ----
(Decrease)/increase in cash and bank overdrafts in the year (1,956) 1,384
Exchange adjustments (254) 233
Cash and bank overdrafts at beginning of year 3,972 2,355
---- ----
Cash and bank overdrafts at end of year 1,762 3,972
---- ----
Cash and bank overdrafts at end of year comprise:
Cash and cash equivalents 2,005 4,209
Overdrafts (243) (237)
---- ----
1,762 3,972
---- ----
CASH FLOW STATEMENT
Three months ended 31st December 2006
Q4 2006 Q4 2005
£m £m
---- ----
Profit after tax 1,205 1,151
Tax on profits 505 455
Share of after tax profits of associates and joint ventures (13) (13)
Finance income/expense 3 40
Depreciation and other non-cash items 251 434
Increase in working capital (11) (255)
Increase/(decrease) in other net liabilities 6 (92)
---- ----
Cash generated from operations 1,946 1,720
Taxation paid (441) (435)
---- ----
Net cash inflow from operating activities 1,505 1,285
---- ----
Cash flow from investing activities
Purchase of property, plant and equipment (470) (348)
Proceeds from sale of property, plant and equipment 11 (9)
Purchase of intangible assets (69) (93)
Proceeds from sale of intangible assets (8) (3)
Purchase of equity investments (22) (5)
Proceeds from sale of equity investments 10 13
Share transactions with minority shareholders 1 (4)
Purchase of businesses, net of cash acquired (256) (883)
Disposals of businesses and interests in associates 2 (2)
Investment in associates and joint ventures (5) -
Interest received 102 90
Dividends from associates and joint ventures 2 2
---- ----
Net cash outflow from investing activities (702) (1,242)
---- ----
Cash flow from financing activities
Increase in liquid investments (6) (684)
Proceeds from own shares for employee share options 31 45
Issue of share capital 55 171
Purchase of Treasury shares (534) (374)
Net increase in/(repayment of) short-term loans 135 (489)
Net repayment of obligations under finance leases (7) (11)
Interest paid (167) (60)
Dividends paid to shareholders (620) (567)
Dividends paid to minority interests (6) (8)
Other financing cash flows 116 21
---- ----
Net cash outflow from financing activities (1,003) (1,956)
---- ----
Decrease in cash and bank overdrafts in the period (200) (1,913)
Exchange adjustments (46) 20
Cash and bank overdrafts at beginning of period 2,008 5,865
---- ----
Cash and bank overdrafts at end of period 1,762 3,972
---- ----
Cash and bank overdrafts at end of period comprise:
Cash and cash equivalents 2,005 4,209
Overdrafts (243) (237)
---- ----
1,762 3,972
---- ----
RECONCILIATION OF CASH FLOW TO MOVEMENTS IN NET DEBT
2006 2005
£m £m
---- ----
Net debt at beginning of the year (1,237) (1,984)
(Decrease)/increase in cash and bank overdrafts (1,956) 1,384
Cash outflow/(inflow) from liquid investments 55 (550)
Net increase in long-term loans - (912)
Net repayment of short-term loans 739 857
Net repayment of obligations under finance leases 34 36
Net non-cash funds of businesses acquired - (68)
Exchange adjustments (9) 39
Other non-cash movements (76) (39)
---- ----
(Increase)/decrease in net debt (1,213) 747
---- ----
Net debt at end of the year (2,450) (1,237)
---- ----
FINANCIAL REVIEW - CASH FLOW
Cash generated from operations was £8,203 million in 2006. This represents an increase of £538 million over 2005,
principally due to higher operating profits which were partially offset by an increase in working capital and a decrease
in other net liabilities. The operating cash flow is in excess of the funds needed for the routine cash flows of tax,
capital expenditure on property, plant and equipment and dividend payments, together amounting to £7.8 billion.
Taxation paid during the year included the gross payment of $3.3 billion (£1.8 billion) under the transfer pricing
dispute settlement with the US Internal Revenue Service (see 'Taxation' on page 13). The purchase of businesses cost
£273 million. Receipts of £467 million arose from the exercise of share options: £151 million from shares held by the
ESOP Trusts and £316 million from the issue of new shares. In addition, £1,348 million was spent in the year on
purchasing the company's shares to be held as Treasury shares.
EXCHANGE RATES
The results and net assets of the Group, as reported in sterling, are affected by movements in exchange rates between
sterling and overseas currencies. GSK uses the average of exchange rates prevailing during the period to translate the
results and cash flows of overseas Group subsidiary and associated undertakings into sterling and period-end rates to
translate the net assets of those undertakings. The currencies which most influence these translations, and the
relevant exchange rates, are:
2006 2005 Q4 2006 Q4 2005
Average rates: ---- ---- ---- ----
£/US$ 1.85 1.82 1.94 1.73
£/Euro 1.47 1.46 1.50 1.46
£/Yen 215.00 200.00 227.00 203.00
Period-end rates:
£/US$ 1.96 1.72 1.96 1.72
£/Euro 1.48 1.46 1.48 1.46
£/Yen 233.00 203.00 233.00 203.00
During 2006, average sterling exchange rates were stronger against the US dollar, the Euro and the Yen compared with
2005. Comparing 2006 period-end rates with 2005 period-end rates, sterling was stronger against the US dollar, the Euro
and the Yen.
LEGAL MATTERS
The Group is involved in various legal and administrative proceedings, principally product liability, intellectual
property, tax, anti-trust and governmental investigations and related private litigation concerning sales, marketing and
pricing. The Group makes provision for those proceedings on a regular basis and may make additional significant
provisions for such legal proceedings, as required in the event of further developments in those matters, consistent
with generally accepted accounting principles. Litigation, particularly in the USA, is inherently unpredictable and
excessive awards that may not be justified by the evidence can occur. The Group could in the future incur judgments or
enter into settlements of claims that could result in payments that exceed its current provisions by an amount that
would have a material adverse effect on the Group's financial condition, results of operations and cash flows.
Intellectual property claims include challenges to the validity of the patents on various of the Group's products or
processes and assertions of non-infringement of those patents. A loss in any of these cases could result in loss of
patent protection for the product at issue. The consequence of any such loss could be a significant decrease in sales
of that product and could materially affect future results of operations for the Group.
At 31st December 2006, the Group's aggregate provision for legal and other disputes (not including tax matters described
under 'Taxation' on page 13) was over £1.1 billion. The ultimate liability for legal claims may vary from the amounts
provided and is dependent upon the outcome of litigation proceedings, investigations and possible settlement
negotiations.
Developments since the date of the Annual Report as previously updated by the Legal matters sections of the Results
Announcements for the first, second and third quarters of 2006 include:
Intellectual property
With respect to the Group's application to the US Patent and Trademark Office (USPTO) for re-issue of its combination
patent for Advair, in January 2007 the Group received a Notice of Allowance finding the pharmaceutical composition
claims patentable. The re-issue patent will have the same September 2010 expiration date as the original combination
patent. In addition, the Group holds other US patents relating to Advair, including various patents relating to the
Diskus device which expire over a period from 2011 to 2016, and various patents relating to the HFA formulation and MDI
device which expire over a period from 2014 to 2017.
With respect to the Group's patent infringement action against Cobalt Pharmaceuticals in respect of Imitrex, the Group
reached a settlement with Cobalt in November 2006 which provides that Cobalt may distribute a generic version of
sumatriptan tablets in the USA with an expected launch date early in the first quarter of 2009.
With respect to the Group's patent infringement action against Spectrum Pharmaceuticals in respect of Imitrex, the Group
reached a settlement with Spectrum in December 2006 which provides that Spectrum may exclusively distribute authorised
generic versions of certain sumatriptan injection products in the USA with an expected launch during GSK's sumatriptan
paediatric exclusivity period which begins in August 2008, with such launch occurring not later than early November
2008.
With respect to the trial of the Group's patent infringement action in respect of Requip against Teva Pharmaceuticals in
the US District Court for the District of Delaware, in December 2006 the judge ruled at the conclusion of the trial that
the Group's patent on the use of ropinirole (the active ingredient in Requip) to treat Parkinson's disease is novel and
non-obvious rejecting Teva's claims on those grounds. Teva's further claim that the patent is unenforceable for
inequitable conduct remains before the judge as the evidence was not reviewed at the trial. This issue is to be decided
on the basis of deposition testimony and documents and consideration of further potential filings by the parties.
Teva's original challenge to the Group's basic compound patent was withdrawn before the trial, and Teva has accepted
that the FDA will not approve its product prior to expiration of that patent.
With respect to the Group's patent infringement action against Ranbaxy Laboratories in respect of Valtrex, on 1st
February 2007, Ranbaxy received FDA approval for its generic valacyclovir product, and notified the Group that it sought
to market the product in the USA. The Group will apply to the court for a preliminary injunction prohibiting launch of
this product pending completion of the lawsuit. Under the terms of an agreement between the companies, previously
approved by the court, if the Group applies for such an injunction within 45 days, Ranbaxy will not launch its product
until the court either rules on the preliminary injunction or decides the pending court case. No trial date has yet
been set for the pending court case.
With respect to Wellbutrin XL, the US Food and Drug Administration (FDA) has approved Abbreviated New Drug Applications
for Anchen Pharmaceuticals for a generic form of Wellbutrin XL (150mg and 300mg tablets) and Impax Laboratories for a
generic form of 300mg tablets. Marketing of a 300mg tablet generic version of Wellbutrin XL began in December 2006.
With respect to the Group's patent infringement action against Teva Pharmaceuticals in the US District Court for the
District of New Jersey in respect of the basic compound patent (expiring in 2012) and the maleate salt patent (expiring
in 2015) for Avandia, a trial date has been set for 6th August 2007. Dr Reddy's Laboratories' challenge of the maleate
salt patent in the same court has been combined with the Teva action for trial. Neither Dr Reddy's nor the other
manufacturers that have filed ANDAs for generic forms of Avandia have challenged the validity of the basic compound
patent.
Anti-trust
With respect to anti-trust actions initiated against the Group on the basis of the Group's actions in 2003 to reduce
illegal importation of prescription drugs from Canada, in November 2006 the US Court of Appeals for the Eighth Circuit
affirmed the decision of the US District Court for the District of Minnesota which had granted the Group's motion to
dismiss the purported class actions that had been consolidated for trial before that court. In December 2006, the trial
judge, for the California state court anti-trust action filed on behalf of a number of retail pharmacies, granted the
Group's motion for summary judgment. The remaining state anti-trust case filed by the Minnesota state attorney general
is still in the discovery phase.
Commercial and other litigation
In December 2006, two purported class actions were filed in the US District Courts for the Central and Southern
Districts of California against the Group on behalf of all the Group's US pharmaceutical sales representatives alleging
that those representatives are entitled to overtime pay. Similar actions have been filed against other pharmaceutical
companies. The cases are in their early stages.
Developments with respect to tax matters are described in 'Taxation' on page 13.
ACCOUNTING PRESENTATION AND POLICIES
This unaudited Results Announcement containing condensed financial information for the twelve and three months ended
31st December 2006 is prepared in accordance with the Listing Rules of the London Stock Exchange, IAS 34 'Interim
Financial Reporting' and the accounting policies set out in the Annual Report 2005, except that IFRIC Interpretation 4 '
Determining whether an arrangement contains a lease' and an amendment to IAS 39 'Financial guarantee contracts' have
been implemented in 2006. Neither change has had a material effect on the current or prior periods. This Results
Announcement does not constitute statutory accounts of the Group within the meaning of section 240 of the Companies Act
2005.
The income statement, statement of recognised income and expense and cash flow statement for the year ended, and the
balance sheet at, 31st December 2005 have been derived from the full Group accounts published in the Annual Report 2005,
which have been delivered to the Registrar of Companies and on which the report of the independent auditors was
unqualified and did not contain a statement under either section 237(2) or section 237(3) of the Companies Act 1985.
Data for market share and market growth rates are GSK estimates based on the most recent data from independent external
sources and, where appropriate, are valued in sterling at relevant exchange rates. Figures quoted for product market
share reflect sales by GSK and licensees.
In order to illustrate underlying performance, it is the Group's practice to discuss its results in terms of constant
exchange rate (CER) growth. This represents growth calculated as if the exchange rates used to determine the results of
overseas companies in sterling had remained unchanged from those used in the previous year. All commentaries are
presented in terms of CER unless otherwise stated.
INVESTOR INFORMATION
Preliminary Announcement of Annual Results for 2006
This Announcement was approved by the Board of Directors on Thursday 8th February 2007.
The income statement, statement of recognised income and expense, and cash flow statement for the year ended 31st
December 2006 and the balance sheet at that date, are subject to completion of the audit and may also change should a
significant adjusting event occur before the approval of the Annual Report 2006 on 28th February 2007.
Financial calendar
The company will announce first quarter 2007 results on 25th April 2007. The first interim dividend for 2007 will have
an ex-dividend date of 2nd May 2007 and a record date of 4th May 2007. It will be paid on 12th July 2007.
Internet
This Announcement and other information about GSK are available on the company's website at: http://www.gsk.com.
This information is provided by RNS
The company news service from the London Stock Exchange FR OKFKNDBKDQBK
Latest directors dealings
- 1 day ago Banco Santander S.A.
- 1 day ago Banco Santander S.A.
- 1 day ago Banco Santander S.A.
- 1 day ago Banco Santander S.A.
- 1 day ago Georgia Capital